期刊
EUROPEAN JOURNAL OF IMMUNOLOGY
卷 42, 期 3, 页码 790-798出版社
WILEY
DOI: 10.1002/eji.201142108
关键词
B cells; Multiple sclerosis; Natalizumab; Progressive multifocal leukoencephalopathy
类别
资金
- Gemeinnutzige Hertie Stiftung
- Deutsche Forschungsgemeinschaft [JE 530/1-1]
Natalizumab, an antibody against the a4 subunit of a4 integrins, has been approved for multiple sclerosis (MS) therapy based on its high efficacy and safety profile. However, natalizumab has been associated with the development of progressive multifocal leukoencephalopathy (PML), a disorder caused by JC virus (JCV) infection. In order to improve our understanding of the mechanism of action of natalizumab and to identify possible risk factors for PML development, we have characterized in detail the cell blood composition in MS patients treated with natalizumab for more than 30 months. Natalizumab induced the release of lymphoid- but not myeloid precursor cells, which resulted in a chronic increase ofT-, NK- and particularly B cells. While the percentage of recent thymic emigrants (RTEs), na?ve, effector or memory T cells remained unchanged during treatment, a higher percentage of memory- and marginal zone (MZ)-like, but not of na?ve B cells, was observed, which most likely is due to a decreased retention of these cells within the splenic MZ. The ability of natalizumab to influence B-cell migration and homeostasis through the splenic MZ, where JCV has been detected, adds to the list of natalizumab effects and may contribute to PML development by disseminating JCV.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据